Argent Trust Co Boosts Johnson & Johnson Holdings

Institutional investor increases stake in pharmaceutical giant by 2.5% in Q3

Published on Feb. 28, 2026

Got story updates? Submit your updates here. ›

Argent Trust Co, a financial services firm, has increased its position in Johnson & Johnson (NYSE:JNJ) by 2.5% during the third quarter, according to a recent SEC filing. The fund now owns 181,290 shares of the company's stock, valued at $33.6 million.

Why it matters

Johnson & Johnson is one of the world's largest and most diversified healthcare companies, with a strong presence in pharmaceuticals, medical devices, and consumer products. Institutional investor activity in the stock can provide insights into market sentiment and expectations around the company's performance.

The details

Argent Trust Co acquired an additional 4,349 shares of Johnson & Johnson during the third quarter, bringing its total holdings to 181,290 shares. This represents approximately 1.2% of Argent's overall portfolio. The purchase comes as Johnson & Johnson's stock price has risen significantly in recent months, reaching new all-time highs.

  • Argent Trust Co increased its Johnson & Johnson holdings during the 3rd quarter of 2026.

The players

Argent Trust Co

A financial services firm that manages investments and provides wealth management services.

Johnson & Johnson

A multinational pharmaceutical and consumer goods company headquartered in New Brunswick, New Jersey.

Got photos? Submit your photos here. ›

The takeaway

Argent Trust Co's increased stake in Johnson & Johnson reflects the company's continued appeal to institutional investors, despite the stock's recent run-up in price. As a diversified healthcare conglomerate, Johnson & Johnson's performance is closely watched by the investment community.